<DOC>
	<DOCNO>NCT01608841</DOCNO>
	<brief_summary>The purpose study investigate influence epidermal growth factor receptor mutation efficacy erlotinib gemcitabine metastatic pancreatic cancer .</brief_summary>
	<brief_title>The Role EGFR Mutations Pancreatic Cancer Patients Receiving Gemcitabine With Without Erlotinib</brief_title>
	<detailed_description>The influence EGFR mutation efficacy treatment without erlotinib metastatic pancreatic cancer determine .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>metastatic chemotherapyna√Øve pancreatic cancer patient histologically confirm adequate sample analysis Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; = 2 absolute neutrophil count ( ANC ) &gt; = 1,500/mm3 platelet count &gt; = 100,000/mm3 serum creatinine &lt; = 1.5 mg/dL aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 5 time upper limit normal absence malignancy serious medical psychological illness would preclude informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>